<DOC>
	<DOCNO>NCT01760980</DOCNO>
	<brief_summary>The objective study assess bioequivalence test product , Exemestane 25 mg tablet Actavis Group PTC ehf . Iceland , reference product , Aromasin® ( exemestane ) 25 mg tablet Pharmacia &amp; Upjohn Company , Division Pfizer Inc. , New York , United States America healthy male postmenopausal female subject , fast condition</brief_summary>
	<brief_title>Pivotal Bioequivalence Study Exemestane 25 mg Tablets Under Fasting Conditions Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . Healthy male subject , 18 55 year age postmenopausal female subject , 18 year old 75 year age ( inclusive time screen ) . 2 . Body Mass Index ( BMI ) 19 33 kg/m2 ( relate body mass within 15 % ideal body mass height age ) . 3 . Body mass le 50 kg . 4 . Medical history , vital sign , physical examination , standard 12lead electrocardiogram ( ECG ) laboratory investigation must clinically acceptable within laboratory reference range relevant laboratory test , unless investigator considers deviation irrelevant purpose study . 5 . Nonsmoker mild moderate smoker ( ≤ 10 cigarette daily ) . 6 . Females , : Serum folliclestimulating hormone ( FSH ) ≥ 25.8 mIU/mL AND serum estradiol level ≤ 54.7 pg/mL screening . Not childbearing potential , e.g. , surgically sterilize , undergone hysterectomy , amenorrhea ≥ 12 month consider postmenopausal . Note : In postmenopausal woman , value serum pregnancy test may slightly increase , increase upon repeat , female include study . • Not thyroid hormone replacement therapy stable thyroid hormone replacement therapy least 3 month first administration IMP . Not statin therapy stable statin therapy least 3 month first administration IMP . • Blood pressure measurement within acceptable range ; , diagnose hypertension , stable therapy least 3 month first administration IMP . Note : Treatment calcium channel blocker NOT allow . 7 . Written consent give participation study . 1 . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . 2 . Current alcohol use &gt; 21 unit alcohol per week male &gt; 14 unit alcohol per week female . 3 . History regular exposure substance abuse ( alcohol ) within past year . 4 . Use medication , prescribe overthecounter herbal remedy , within 2 week prior first administration IMP , except medication allow per inclusion criterion ( Section 7.3.1 ) medication affect outcome study opinion investigator . 5 . Female hormone replacement therapy ( medicine contain estrogen , include health food product menopausal symptom , may contain natural estrogen ) , within 2 week prior first administration IMP . 6 . Participation another study experimental drug , last administration previous IMP within 8 week first administration IMP study . 7 . Donation loss blood equal exceed 500 mL 8 week first administration IMP . 8 . Treatment within previous 3 month first administration IMP drug welldefined potential adversely affect major organ system . 9 . A major illness 3 month commencement screening period . 10 . History hypersensitivity allergy IMP excipients related medication . 11 . History bronchial asthma bronchospastic disease within past 5 year . 12 . History epilepsy . 13 . History porphyria . 14 . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . 15 . Systolic blood pressure &gt; 150 mmHg &lt; 95 mmHg , and/or diastolic blood pressure &gt; 95 mmHg &lt; 50 mmHg either supine standing position screen . 16 . Resting pulse &gt; 100 beat per minute &lt; 45 beat per minute either supine standing position screen . 17 . Positive serology test human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C syphilis . 18 . Positive urine screen drug abuse . 19 . Positive pregnancy test . 20 . Female subject premenopausal endocrine status , include pregnant lactating woman . 21 . Clinically diagnosed peptic ulceration within past 5 year . 22 . History bleed disorder . 23 . Vegetarian abnormal diet ( whatever reason ) . 24 . Any specific investigational product safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rate extend absorption Exemestane</keyword>
</DOC>